This article is more than 5 years old. Information may no longer be current.

Saroglitazar magnesium lowers ALT, hepatic fat in NAFLD

Results from the EVIDENCES IV trial showed that saroglitazar magnesium achieved its primary endpoint of reduced alanine aminotransferase in patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, according to a press release from Zydus Calida.

“Saroglitazar 4 mg significantly improved liver biochemistries, hepatic steatosis, dyslipidemia, and insulin resistance, with no weight gain or fluid retention,” Naga P. Chalasani, MD, principal investigator from the Indiana University School of Medicine, said in the release. “These results are quite encouraging as there is a significant unmet need for patients with NAFLD and NASH for a drug that improves not just the liver disease, but important comorbidities such as insulin resistance and dyslipidemia.”

The randomized control phase 2 trial comprised 106 patients with NAFLD, including patients with who had progressed to NASH. At 16 weeks, treated patients achieved significantly reduced ALT levels and hepatic fat content compared with placebo.

“We are happy with the positive results that saroglitazar magnesium has shown in the EVIDENCES IV trial,” Pankaj R. Patel, chairman of the Zydus Group, said. “We look forward to presenting the detailed data in upcoming scientific conferences and publishing the study findings in peer-reviewed scientific journals.”

Reference: www.zyduscalida.com